Orbital Therapeutics vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orbital Therapeutics is a next-gen RNA biotech that raised $270M Series A in 2023; advancing circular RNA and in vivo CAR-T programs for autoimmune disease; Bristol Myers Squibb announced a $1.5B acquisition in 2025;
About
Orbital Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, with a mission to unlock the full potential of RNA medicines. The company operates at the frontier of RNA biology, advancing a platform that spans circular RNA, self-amplifying RNA, and in vivo CAR-T cell therapies — technologies designed to go beyond the mRNA approaches pioneered during the COVID-19 era. Orbital was co-founded by leading RNA scientists and backed by ARCH Venture Partners, a16z Bio + Health, Newpath Partners, the Abu Dhabi Growth Fund, and Redmile Group, among others.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Orbital Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.